916 related articles for article (PubMed ID: 30205045)
1. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.
Razavi P; Chang MT; Xu G; Bandlamudi C; Ross DS; Vasan N; Cai Y; Bielski CM; Donoghue MTA; Jonsson P; Penson A; Shen R; Pareja F; Kundra R; Middha S; Cheng ML; Zehir A; Kandoth C; Patel R; Huberman K; Smyth LM; Jhaveri K; Modi S; Traina TA; Dang C; Zhang W; Weigelt B; Li BT; Ladanyi M; Hyman DM; Schultz N; Robson ME; Hudis C; Brogi E; Viale A; Norton L; Dickler MN; Berger MF; Iacobuzio-Donahue CA; Chandarlapaty S; Scaltriti M; Reis-Filho JS; Solit DB; Taylor BS; Baselga J
Cancer Cell; 2018 Sep; 34(3):427-438.e6. PubMed ID: 30205045
[TBL] [Abstract][Full Text] [Related]
2. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ
Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers.
Ng CW; Tsang YTM; Gershenson DM; Wong KK
Br J Cancer; 2024 May; 130(11):1875-1884. PubMed ID: 38582811
[TBL] [Abstract][Full Text] [Related]
4. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
5. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
[TBL] [Abstract][Full Text] [Related]
6. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.
Hartmaier RJ; Trabucco SE; Priedigkeit N; Chung JH; Parachoniak CA; Vanden Borre P; Morley S; Rosenzweig M; Gay LM; Goldberg ME; Suh J; Ali SM; Ross J; Leyland-Jones B; Young B; Williams C; Park B; Tsai M; Haley B; Peguero J; Callahan RD; Sachelarie I; Cho J; Atkinson JM; Bahreini A; Nagle AM; Puhalla SL; Watters RJ; Erdogan-Yildirim Z; Cao L; Oesterreich S; Mathew A; Lucas PC; Davidson NE; Brufsky AM; Frampton GM; Stephens PJ; Chmielecki J; Lee AV
Ann Oncol; 2018 Apr; 29(4):872-880. PubMed ID: 29360925
[TBL] [Abstract][Full Text] [Related]
7. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.
Normanno N; Di Maio M; De Maio E; De Luca A; de Matteis A; Giordano A; Perrone F;
Endocr Relat Cancer; 2005 Dec; 12(4):721-47. PubMed ID: 16322319
[TBL] [Abstract][Full Text] [Related]
9. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S
Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
12. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA mutations in endocrine-resistant breast cancer.
Schagerholm C; Robertson S; Toosi H; Sifakis EG; Hartman J
Sci Rep; 2024 May; 14(1):12542. PubMed ID: 38822093
[TBL] [Abstract][Full Text] [Related]
14. Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
Robinson DR; Wu YM; Vats P; Su F; Lonigro RJ; Cao X; Kalyana-Sundaram S; Wang R; Ning Y; Hodges L; Gursky A; Siddiqui J; Tomlins SA; Roychowdhury S; Pienta KJ; Kim SY; Roberts JS; Rae JM; Van Poznak CH; Hayes DF; Chugh R; Kunju LP; Talpaz M; Schott AF; Chinnaiyan AM
Nat Genet; 2013 Dec; 45(12):1446-51. PubMed ID: 24185510
[TBL] [Abstract][Full Text] [Related]
15. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
Newby JC; Johnston SR; Smith IE; Dowsett M
Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor mutations and their role in breast cancer progression.
Alluri PG; Speers C; Chinnaiyan AM
Breast Cancer Res; 2014 Dec; 16(6):494. PubMed ID: 25928204
[TBL] [Abstract][Full Text] [Related]
17. Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
Kurland BF; Peterson LM; Lee JH; Schubert EK; Currin ER; Link JM; Krohn KA; Mankoff DA; Linden HM
Clin Cancer Res; 2017 Jan; 23(2):407-415. PubMed ID: 27342400
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.
Grote I; Bartels S; Kandt L; Bollmann L; Christgen H; Gronewold M; Raap M; Lehmann U; Gluz O; Nitz U; Kuemmel S; Zu Eulenburg C; Braun M; Aktas B; Grischke EM; Schumacher C; Luedtke-Heckenkamp K; Kates R; Wuerstlein R; Graeser M; Harbeck N; Christgen M; Kreipe H
Cancer Med; 2021 Dec; 10(23):8581-8594. PubMed ID: 34779146
[TBL] [Abstract][Full Text] [Related]
19. Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer.
Zhao H; Ou-Yang F; Chen IF; Hou MF; Yuan SS; Chang HL; Lee YC; Plattner R; Waltz SE; Ho SM; Sims J; Wang SC
Neoplasia; 2010 Mar; 12(3):214-23. PubMed ID: 20234815
[TBL] [Abstract][Full Text] [Related]
20. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
Sammons S; Shastry M; Dent S; Anders C; Hamilton E
Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
